inc buy pt unfavor rule franchise bankruptci believ
stop momentum rais pt analyst stephen anderson full summari
time restaur inc gtim buy pt hurrican florenc time bad daddi setback
temporari view maintain buy pt analyst stephen anderson full summari
mvc capit inc mvc buy pt cover dividend still progress reiter buy rate price target
genprex inc gnpx buy pt establish suppli gmp-valid resum lung cancer
corpor event call maxim salesperson inform
beigen ltd bgne cover mccarthi institut group dinner nyc cfo howard liang tue oct
ellex medic laser elx asx cover vendetti ndr ny ceo tom spurl tue oct
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
california restaur tour habt host orang counti ca mon tue
maxim group first annual tmt confer host chokshi klee tue dec
cover klee ndr milwauke madison cfo stan sutula tue dec
cover klee ndr chicago cfo stan sutula wed dec
cover diana ndr ny cfo lui massiani mon oct
unfavor rule franchise bankruptci
believ stop momentum rais pt
maintain buy rais price target
compani septemb draw close
wednesday septemb bankruptci court rule could
take oper bankrupt franchise rmh hold
applebe second largest franchise restaur
model potenti addit closur lower ep estim
vs consensu guidanc
ep estim vs consensu ep
estim unchang vs consensu
continu expect improv fundament applebe ihop
believ rmh setback prove temporari maintain
among top restaur pick
upwardli revis price target base unchang ep
estim
unfavor rule franchise bankruptci case
believ disrupt prove temporari wednesday septemb
bankruptci court rule could take oper bankrupt
franchise rmh hold pave way restaur liquid given
improv health overal applebe system recent quarter expect
franchise bid rmh properti howev think prudent
assum mani properti total may close thu
exit applebe system altogeth estim acceler rmh-relat
closur reduc ep decemb much
nevertheless expect expens mitig later
lower sg legal expens relat case restart unit growth
applebe system particularli oversea
continu see improv fundament applebe ihop
believ rmh setback prove temporari applebe
system sale comp estim compar
perform thank part repris popular all-you-can-
riblet tender limited-time-off lto well popular drink special later
quarter ihop system sale maintain forecast
comp thank mostli revamp ihop go off-premis platform support
expand mobil platform new third-parti deliveri risk outlook
lap posit comp begin decemb believ
sale momentum continu particularli applebe
ihop build off-premis presenc expect share climb wall
worri next coupl quarter
remain one top pick still see signific upsid share
price share trade revis ep estim
unchang ep estim vs five-year averag
full-servic industri averag forward ev/ebitda vs five-
year averag increasingli confid manag abil gener
posit comp maxim return use new base valuat year
equal weight forward price-to-earnings multipl forward ev/ebitda multipl sum-of-
part methodolog arriv upwardli revis price target
above-averag short posit float compar weight
industri averag believ posit result potenti trigger short-
click full note
hurrican florenc time bad daddi
setback temporari view maintain buy pt
maintain buy rate price target time restaur
gtim ahead like releas septemb preliminari sale
believ hurrican florenc hurt sale bad daddi
ttm sale thu reduc quarterli comp estim
maintain comp forecast time ttm
estim loss per share loss per share
unchang comp estim time
howev rais comp estim bad daddi
nevertheless still believ gtim attract valuat even
share price bounc significantli februari low
believ hurrican florenc hurt sale bad daddi thu reduc
quarterli comp estim bad daddi
locat bad daddi system north carolina five close
advanc hurrican florenc although locat sinc reopen
estim hurrican reduc comp much ep
much expect comp bad daddi remain sluggish though
posit rang least compani shi
tv advertis decemb lap strong weather-driven comp
march look ahead expect bad daddi full-year comp
prior estim guidanc project bad
daddi comp run firmli posit rang third-parti
deliverywhich test colorado locat locat roll
system-wid bad daddi lap hurrican florence-rel closur
maintain comp forecast time model
deceler ttm comp pace manag eschew expens
tv advertis denver market ahead midterm elect expect
comp remain sluggish though posit rang least
compani shi tv advertis decemb
lap strong weather-driven comp march nevertheless model full-
year comp assum comp rebound level
nevertheless still believ gtim attract valuat even share
price bounc significantli februari low even sinc doubl sinc
februari gtim share still trade adjust ebitda estim
adjust ebitda estim growth thesi remain intact
compani believ gtim compel valuat particularli bad
daddi unit growth shift increasingli lower-cost market expect food
cost remain benign combin valuat model use
base valuat year use forward ebitda multipl time
forward ebitda multipl bad daddi use model arriv
click full note
establish suppli gmp-valid resum
lung cancer
genprex announc enter suppli agreement contract
aldevron privat suppli genprex tumor suppressor
candid plasmid dna gene deliv oncoprex
genprex gene therapi candid non-smal cell lung cancer nsclc
genprex gmp-valid suppli high-qual plasmid dna vector
util oncoprex clinic trial
recal focu genprex differenti approach gene
therapi make oncoprex platform oncoprex deliv gene
payload without need viral vector aav lentiviru retro viru other
avoid potenti issu like immunogen manufactur
process also significantli less costli
conclus view agreement increment posit
compani await resumpt phase portion phase
combin trial oncoprex erlotinib nsclc
oncoprex compos tumor suppressor gene encapsul
posit charg nanovesicl nonvir deliveri system select affin
neg charg cancer cell provid system deliveri regardless
patient molecular profil multimod activ includ inhibit
multipl oncogen kinas egfr pdgfr akt etc induct apoptosi
stimul immun respons compani convers
fda regard possibl expedit approv pathway oncoprex anticip
guidanc anticip genprex resum phase portion phase
combin trial oncoprex/erlotinib nsclc data readout
like time-frame
tumor suppressor candid multifunct gene play critic
role cancer suppress well normal cell regul found
frequent delet inactiv due genet alter earli develop
cancer type includ lung breast nsclc lack tumor
suppressor gene although target therapeut checkpoint inhibitor
produc durabl result resist develop time via activ altern
approv cancer therapeut restor express
nanovesicle-bas gene therapi could potenti block bypass
pathway mediat drug resist would impact patient drug-resist
click full note
cover dividend still progress reiter buy
liquid sale largest invest pipelin yield
invest plan million share repurchas mvc appear
well-posit transit invest portfolio alloc higher
percentag yield invest cover quarterli dividend
net origin expect due
competit lend environ expect environ persist
base newly-introduc ep estim anticip
mvc cover dividend
mvc share current trade reiter buy
rate maintain price target expect mvc make
progress plan aid million share repurchas
mvc commit price target equat forward
estim slight discount level believ
bdc trade current environ discount warrant
mvc lower dividend yield versu bdc
relev peer
result summari septemb mvc report core nii
exclud non-cash neg incent compens versu estim
gaap net loss per share primarili due unreal loss two publicli
trade invest currenc convers dividend gaap
net loss
data mvc gross origin million payoff sale
million expect due competit lend
environ expect environ persist forecast
modest portfolio growth howev mvc commit million
share repurchas combin portfolio rotat produc increas
earn earli mvc use short-term invest pay credit facil
leverag decreas equiti
introduc ep estim increas annual
core nii driven share repurchas portfolio rotat modest
portfolio growth competit lend environ persist unlik
mvc abl cover dividend view page
reiter buy rate next four quarter expect dividend
yield stock price appreci price target
result estim total return beyond
time-frame mvc attain materi higher alloc yield invest
expect compani rais dividend in-line peer result
elimin discount much higher stock price
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
